News and Information-Learn About Hepatitis, Liver Cirrhosis, and Others
A Member of the Healthscout Network
 Printer Friendly  Send to a Friend

Artificial Arteries Might Aid Bypass Patients

The lab-grown vessels are working well in rats, researchers say

FRIDAY, June 15 (HealthDay News) -- U.S. researchers have developed artificial blood vessels that could help ease the demand for new sources of grafts in patients with heart and kidney disease.

A team at the University of Pittsburgh School of Medicine engineered the artificial blood vessels by "seeding" muscle-derived stem cells (MDSCs) inside a biodegradable, porous, tubular polyester urethane scaffold. The vessels were cultured for seven days and then implanted in the abdominal aortas of rats.

Advertisement
Related Stories
 border=
Organ Donation: An Advancing Science Hindered by Supply Shortages
Immune Molecule Key to Preventing Organ Rejection
Non-Surgical Approach Can Treat Lung Cancers
Related Videos
 border=
Blood Cleaner
High Tech Liver Surgery
Heart Transplant Breakthrough
Related Slides
 border=
Hepatitis
Liver Cirrhosis
Liver Transplant
Related Encyclopedia
 border=
Arteriohepatic Dysplasia
Fatty Liver
Hemochromatosis


When examined eight weeks after implantation, the grafted blood vessels had a high blockage-free rate and exhibited tissue formation consistent with a mature artery, the researchers said.

Their findings were presented this week at the Tissue Engineering and Regenerative Medicine International Society's North America Chapter meeting in Toronto.

The researchers said their results demonstrated the feasibility of the technology for use in humans.

"The next step is to demonstrate the use of the tissue-engineered blood vessel in a larger animal model, such as a pig, which has a coagulation system more similar to that in humans," research team leader David A. Vorp, associate professor of surgery and bioengineering, said in a prepared statement.

"The advantage of our approach is that the graft could utilize the patient's own stem cells and be ready for implantation almost immediately or, at most, after a relatively short culture period. This suggests that we could make these available "off-the-shelf," which is an essential element for clinical translation," said Vorp, who is also a faculty member of the university's McGowan Institute for Regenerative Medicine.

Currently, veins taken from the patient's leg are most common source of coronary artery bypass grafting, even though many vein grafts eventually fail. Arterial grafts are preferred, because they're less likely to become obstructed. However, arterial grafts are in short supply, because many patients require multiple grafts, according to background information in a news release about the study.

More information

The U.S. National Heart, Lung, and Blood Institute has more about coronary artery bypass grafting.

-- Robert Preidt

SOURCE: University of Pittsburgh Schools of the Health Sciences, news release, June 15, 2007

Copyright © 2007 ScoutNews, LLC. All rights reserved.
Last updated 6/15/2007



Disclaimer: The information provided on this website is for educational purposes only and does not serve as a replacement for care provided by your own personal health care team. This website does not render or provide medical advice, and no individual should make any medical decisions or change their health behavior based on information provided here. All pertinent content provided on this website should be discussed with your personal physician to evaluate whether it has any relevance to or impact on your specific condition. Reliance on any information provided by this website is solely at your own risk.


Jul 4, 2008
Home
Search
Powered By HealthLine
Patient Guide
News
Health Videos
Health Encyclopedia
Health News Archive
Affiliate Information
HealthScout Network
Contact Us
Newsletters
Privacy Policy
Terms of Use

We comply with the HONcode standard for trustworthy health
information:
verify here.
About The HealthScout Network Contact Us
Copyright © 2001. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service  

To find more information on specific conditions, please visit our partner sites: